These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37429697)

  • 1. Cost-effectiveness of measles and rubella elimination in low-income and middle-income countries.
    Levin A; Burgess C; Shendale S; Morgan W; Cw Hutubessy R; ; Jit M;
    BMJ Glob Health; 2023 Jul; 8(7):. PubMed ID: 37429697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation.
    Fu H; Abbas K; Malvolti S; Gregory C; Ko M; Amorij JP; Jit M
    BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 37949503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of measles and rubella vaccination programmes for disease elimination: a modelling study.
    Winter AK; Lambert B; Klein D; Klepac P; Papadopoulos T; Truelove S; Burgess C; Santos H; Knapp JK; Reef SE; Kayembe LK; Shendale S; Kretsinger K; Lessler J; Vynnycky E; McCarthy K; Ferrari M; Jit M
    Lancet Glob Health; 2022 Oct; 10(10):e1412-e1422. PubMed ID: 36113527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress Toward Measles Elimination - South-East Asia Region, 2003-2020.
    Khanal S; Kassem AM; Bahl S; Jayantha L; Sangal L; Sharfuzzaman M; Bose AS; Antoni S; Datta D; Alexander JP
    MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(33):1042-1046. PubMed ID: 35980874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: a modelling study.
    Hartner AM; Li X; Echeverria-Londono S; Roth J; Abbas K; Auzenbergs M; de Villiers MJ; Ferrari MJ; Fraser K; Fu H; Hallett T; Hinsley W; Jit M; Karachaliou A; Moore SM; Nayagam S; Papadopoulos T; Perkins TA; Portnoy A; Minh QT; Vynnycky E; Winter AK; Burrows H; Chen C; Clapham HE; Deshpande A; Hauryski S; Huber J; Jean K; Kim C; Kim JH; Koh J; Lopman BA; Pitzer VE; Tam Y; Lambach P; Sim SY; Woodruff K; Ferguson NM; Trotter CL; Gaythorpe KAM
    Lancet Glob Health; 2024 Apr; 12(4):e563-e571. PubMed ID: 38485425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
    Thompson KM; Badizadegan ND
    Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness, population-level effects, and heath economics of measles and rubella vaccination].
    Wichmann O; Ultsch B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1260-9. PubMed ID: 23990088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress Toward Rubella Elimination - World Health Organization European Region, 2005-2019.
    O'Connor P; Jankovic D; Zimmerman L; Ben Mamou M; Reef S
    MMWR Morb Mortal Wkly Rep; 2021 Jun; 70(23):833-839. PubMed ID: 34111057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress in the elimination of measles and rubella in the WHO European Region].
    Muscat M; Jankovic D; Goel A; Butler R; Pfeifer D
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1225-30. PubMed ID: 23990083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress Toward Measles and Rubella Elimination - India, 2005-2021.
    Murugan R; VanderEnde K; Dhawan V; Haldar P; Chatterjee S; Sharma D; Dzeyie KA; Pattabhiramaiah SB; Khanal S; Sangal L; Bahl S; Tanwar SSS; Morales M; Kassem AM
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(50):1569-1575. PubMed ID: 36520657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economics of rubella: a systematic review to assess the value of rubella vaccination.
    Babigumira JB; Morgan I; Levin A
    BMC Public Health; 2013 Apr; 13():406. PubMed ID: 23627715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the future global dose demand for measles-rubella microarray patches.
    Ko M; Malvolti S; Cherian T; Mantel C; Biellik R; Jarrahian C; Menozzi-Arnaud M; Amorij JP; Christiansen H; Papania MJ; Meltzer MI; Masresha BG; Pastor D; Durrheim DN; Giersing B; Hasso-Agopsowicz M
    Front Public Health; 2022; 10():1037157. PubMed ID: 36726626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.
    Murhekar MV; Gupta N; Hasan AZ; Kumar MS; Kumar VS; Prosperi C; Sapkal GN; Thangaraj JWV; Kaduskar O; Bhatt V; Deshpande GR; Thankappan UP; Bansal AK; Chauhan SL; Grover GS; Jain AK; Kulkarni RN; Sharma SK; Chaaithanya IK; Kharwal S; Mishra SK; Salvi NR; Sharma S; Sarmah NP; Sabarinathan R; Duraiswamy A; Rani DS; Kanagasabai K; Lachyan A; Gawali P; Kapoor M; Shrivastava AK; Chonker SK; Tilekar B; Tandale BV; Ahmad M; Sangal L; Winter A; Mehendale SM; Moss WJ; Hayford K
    Lancet Glob Health; 2022 Nov; 10(11):e1655-e1664. PubMed ID: 36240831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles, mumps, rubella prevention: how can we do better?
    Kauffmann F; Heffernan C; Meurice F; Ota MOC; Vetter V; Casabona G
    Expert Rev Vaccines; 2021 Jul; 20(7):811-826. PubMed ID: 34096442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards elimination of measles and rubella in Italy: Progress and challenges.
    Adamo G; Baccolini V; Massimi A; Barbato D; Cocchiara R; Di Paolo C; Mele A; Cianfanelli S; Angelozzi A; Castellani F; Salerno C; Isonne C; Bella A; Filia A; Del Manso M; Baggieri M; Nicoletti L; Magurano F; Iannazzo S; Marzuillo C; Villari P
    PLoS One; 2019; 14(12):e0226513. PubMed ID: 31841530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles immunity gaps and the progress towards elimination: a multi-country modelling analysis.
    Trentini F; Poletti P; Merler S; Melegaro A
    Lancet Infect Dis; 2017 Oct; 17(10):1089-1097. PubMed ID: 28807627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis.
    Zimmermann M; Frey K; Hagedorn B; Oteri AJ; Yahya A; Hamisu M; Mogekwu F; Shuaib F; McCarthy KA; Chabot-Couture G
    Vaccine; 2019 Sep; 37(41):6039-6047. PubMed ID: 31471147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hot spot: epidemiology of measles and rubella in Germany and the WHO European region].
    Matysiak-Klose D
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1231-7. PubMed ID: 23990084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016.
    Subaiya S; Tabu C; N'ganga J; Awes AA; Sergon K; Cosmas L; Styczynski A; Thuo S; Lebo E; Kaiser R; Perry R; Ademba P; Kretsinger K; Onuekwusi I; Gary H; Scobie HM
    PLoS One; 2018; 13(7):e0199786. PubMed ID: 29965975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.